Journal of International Oncology››2023,Vol. 50››Issue (11): 701-704.doi:10.3760/cma.j.cn371439-20230828-00132
Received:2023-08-28Revised:2023-10-12Online:2023-11-08Published:2024-01-11
| [1] | 谢玲玲, 林荣春, 林仲秋. 2017 NCCN《子宫肿瘤临床实践指南》简介[J].中国实用妇科与产科杂志,2017,33(5): 480-484. DOI:10.19538/j.fk2017050112. |
| [2] | Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J].CA Cancer J Clin,2023,73(1): 17-48. DOI:10.3322/caac.21763. |
| [3] | Post CCB, Westermann AM, Bosse T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer[J].Crit Rev Oncol Hematol,2020,152: 102973. DOI:10.1016/j.critrevonc.2020.102973. |
| [4] | Legge F, Restaino S, Leone L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment[J].Int J Gynecol Cancer,2020,30(2): 193-200. DOI:10.1136/ijgc-2019-000822. pmid:31792085 |
| [5] | Tronconi F, Nero C, Giudice E, et al. Advanced and recurrent endometrial cancer: state of the art and future perspectives[J].Crit Rev Oncol Hematol,2022,180: 103851. DOI:10.1016/j.critrevonc. 2022.103851. |
| [6] | Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase Ⅲ trial (NRG oncology/GOG0209)[J].J Clin Oncol,2020,38(33): 3841-3850. DOI:10.1200/JCO.20.01076. pmid:33078978 |
| [7] | National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasmsr (version 1.2024)[EB/OL]. [2023-08-10]. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. |
| [8] | Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1[J].JAMA Oncol,2015,1(9): 1319-1323. DOI:10.1001/jamaoncol.2015.2151. pmid:26181000 |
| [9] | O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study[J].J Clin Oncol,2022,40(7): 752-761. DOI:10.1200/JCO.21.01874. |
| [10] | Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase ⅡKEYNOTE-158 study[J].J Clin Oncol,2020,38(1): 1-10. DOI:10.1200/JCO.19.02105. pmid:31682550 |
| [11] | Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial[J].JAMA Oncol,2020,6(11): 1766-1772. DOI:10.1001/jamaoncol.2020.4515. |
| [12] | Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer[J].N Engl J Med,2023,388(23): 2159-2170. DOI:10.1056/NEJMoa2302312. |
| [13] | Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J].J Hematol Oncol,2018,11(1): 120. DOI:10.1186/s13045-018-0664-7. |
| [14] | Shan YL, Zhong CJ, Ni Q, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model[J].J Clin Oncol,2021,39(15 suppl): 2581. DOI:10.1200/JCO.2021.39.15_suppl.2581. |
| [15] | Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer[J].N Engl J Med,2022,386(5): 437-448. DOI:10.1056/NEJMoa2108330. |
| [16] | Wei W, Ban X, Yang F, et al. Phase Ⅱ trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer[J].J Immunother Cancer,2022,10(5): e004338. DOI:10.1136/jitc-2021-004338. |
| [17] | Uno K, Yoshihara M, Tano S, et al. Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report[J].BMC Womens Health,2022,22(1): 375. DOI:10.1186/s12905-022-01961-1. pmid:36104694 |
| No related articles found! |
| Viewed | ||||||
| Full text |
|
|||||
| Abstract |
|
|||||
